MARKET

RARE

RARE

Ultragenyx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

141.54
+5.29
+3.88%
After Hours: 141.54 0 0.00% 16:51 02/26 EST
OPEN
138.06
PREV CLOSE
136.25
HIGH
142.29
LOW
134.53
VOLUME
433.92K
TURNOVER
--
52 WEEK HIGH
179.65
52 WEEK LOW
31.99
MARKET CAP
9.48B
P/E (TTM)
-45.0205
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Ultragenyx: Multiple Potential Catalysts Ahead
Ultragenyx (RARE) is on the cusp of transforming itself from a developmental stage entity into a stable, rare-drug behemoth along with industry pioneer Biomarin (BMRN)...
TipRanks.com · 02/19 12:17
Ultragenyx to Present at Upcoming Investor Conferences
NOVATO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announce...
GlobeNewswire · 02/17 21:01
Ultragenyx's Dojolvi Ok'd In Canada For Genetic Metabolic Disorder
Benzinga · 02/17 15:44
Ultragenyx Dojolvi treatment wins Health Canada approval for rare genetic disorder
Ultragenyx Pharmaceutical (RARE) announces that Health Canada has approved Dojolvi (triheptanoin) as a source of calories and fatty acids for the treatment of adult and pediatric patients with long-chain fatty
Seekingalpha · 02/17 14:08
Ultragenyx Announces Health Canada Approval Of Dojolvi For The Treatment Of Long-Chain Fatty Acid Oxidation Disorders In Adults And Children
NOVATO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and
Benzinga · 02/17 13:36
Ultragenyx Announces Approval of Dojolvi(TM) (UX007/triheptanoin) in Canada for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Adults and Children
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that Health Canada has approved Dojolvi(TM) (tri...
GlobeNewswire · 02/17 13:30
Ultragenyx Obtains Canadian Approval of Dojolvi for Treatment of Fatty Acid Oxidation Disorders
MT Newswires · 02/17 11:25
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ultragenyx Pharmaceutical (RARE) and Sanofi (OtherSNYNF)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ultragenyx Pharmaceutical (RARE) and Sanofi (SNYNF).
SmarterAnalyst · 02/16 12:33
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RARE. Analyze the recent business situations of Ultragenyx through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 17 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RARE stock price target is 157.00 with a high estimate of 195.00 and a low estimate of 80.00.
EPS
Institutional Holdings
Institutions: 348
Institutional Holdings: 73.54M
% Owned: 109.85%
Shares Outstanding: 66.95M
TypeInstitutionsShares
Increased
94
4.98M
New
75
1.65M
Decreased
69
2.27M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.06%
Pharmaceuticals & Medical Research
-0.68%
Key Executives
Chairman/Independent Director
Daniel Welch
President/Chief Executive Officer/Director
Emil Kakkis
Chief Financial Officer/Executive Vice President
Mardi Dier
Chief Human Resource Officer/Executive Vice President
Ernie Meyer
Executive Vice President/General Counsel
Karah Parschauer
Executive Vice President
Erik Harris
Executive Vice President
Dennis Huang
Executive Vice President
Thomas Kassberg
Executive Vice President
John Pinion
Other
Camille Bedrosian
Independent Director
William Aliski
Independent Director
Deborah Dunsire
Independent Director
Lars Ekman
Independent Director
Matthew Fust
Independent Director
Michael Narachi
Independent Director
Clay Siegall
Independent Director
Shehnaaz Suliman
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About RARE
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Its product candidates under biologics category include KRN23 (UX023) and recombinant human beta-glucuronidase (rhGUS) (UX003). Its product candidates under small-molecule category include UX007 and aceneuramic acid extended-release (Ace-ER) (UX001). It is also developing recombinant human protective protein cathepsin-A (rhPPCA). KRN23 is a fully human monoclonal antibody. rhGUS is an intravenous (IV) enzyme replacement therapy. UX007 is a substrate replacement therapy. It is developing Ace-ER for the treatment of GNE myopathy. rhPPCA is in preclinical development.

Webull offers kinds of Ultragenyx Pharmaceutical Inc stock information, including NASDAQ:RARE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RARE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RARE stock methods without spending real money on the virtual paper trading platform.